Clene’s (CLNN) cash and cash equivalents totaled $7.9 million as of September 30, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its cash and cash equivalents as of September 30, 2025, together with $1.2 million raised subsequent to September 30, 2025, will be sufficient to fund its operations into the second quarter of 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Buy Rating for Clene’s CNM-Au8 Driven by Promising ALS Treatment Potential and Market Interest
- Is CLNN a Buy, Before Earnings?
- Clene’s CNM-Au8: A Promising Candidate in ALS Treatment with Buy Rating from Justin Walsh
- Clene’s CNM-Au8: A Promising Game-Changer in ALS Treatment with Buy Rating from Justin Walsh
- Clene Enters Equity Distribution Agreement with Canaccord